You are in: eMedicine Specialties > Emergency Medicine > NEUROLOGY Status EpilepticusArticle Last Updated: Sep 13, 2007AUTHOR AND EDITOR INFORMATIONAuthor: J Stephen Huff, MD, Associate Professor of Emergency Medicine and Neurology, Department of Emergency Medicine, University of Virginia Health Sciences Center J Stephen Huff is a member of the following medical societies: American Academy of Emergency Medicine, American Academy of Neurology, American College of Emergency Physicians, and Society for Academic Emergency Medicine Editors: Daniel J Dire, MD, FACEP, FAAP, FAAEM, Clinical Associate Professor, Department of Emergency Medicine, University of Texas-Houston; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; J Stephen Huff, MD, Associate Professor of Emergency Medicine and Neurology, Department of Emergency Medicine, University of Virginia Health Sciences Center; John Halamka, MD, Chief Information Officer, CareGroup Healthcare System, Assistant Professor of Medicine, Department of Emergency Medicine, Beth Israel Deaconess Medical Center; Assistant Professor of Medicine, Harvard Medical School; Charles V Pollack, Jr, MD, MA, FACEP, Professor, Department of Emergency Medicine, University of Pennsylvania College of Medicine; Chairman, Department of Emergency Medicine, Pennsylvania Hospital Author and Editor Disclosure Synonyms and related keywords: generalized convulsive status epilepticus, GCSE, seizure, subtle status epilepticus, nonconvulsive status epilepticus, catecholamine surge, epilepsy, seizure disorder, tonic-clonic activity, persistent tonic seizure, idiopathic seizure disorder, stroke, hypoxic injury, tumor, subarachnoid hemorrhage, trauma, toxicologic effects, electrolyte abnormality, hyponatremia, hypernatremia, hypercalcemia, hepatic encephalopathy, meningitis, brain abscess, encephalitis, metabolic acidosis, isoniazid toxicity, anticonvulsant irregularity INTRODUCTIONBackgroundThe term status epilepticus may be used to describe any continuing type of seizure. This discussion focuses on generalized convulsive status epilepticus (GCSE). Generalized refers to abnormal excessive cortical electrical activity, while convulsive refers to the motor activity of a seizure. Recently, the concept of subtle status epilepticus has emerged. Subtle status epilepticus consists of electrical seizure activity that endures when the associated movements are fragmentary or even absent. This is confusing and is sometimes called a type of nonconvulsive status epilepticus. Subtle status epilepticus, epileptic encephalopathy, and even ICU status are all terms used to refer to this clinical condition of dissociated cortical epileptiform activity from convulsive motor movements. Traditionally, status epilepticus was defined as 30 minutes of continuous seizure activity or a series of seizures without return to full consciousness between the seizures. Many believe that a shorter period of seizure activity causes neuronal injury and that seizure self-termination is unlikely after 5 minutes; some suggest times as brief as 5 minutes to define status epilepticus.1 For purposes of this review, a duration of 5 minutes of continuous generalized convulsive activity is used arbitrarily as part of the definition of GCSE as well as recurrent seizures without a return to consciousness between seizures. PathophysiologySignificant physiologic changes accompany GCSE. Many of these systemic responses are thought to result from the catecholamine surge that accompanies the seizures. Hypertension, tachycardia, cardiac arrhythmias, and hyperglycemia are examples of these systemic effects. Body temperature may increase in patients following the vigorous muscle activity that accompanies GCSE (but, of course, infectious etiologies also must be considered in febrile patients). Lactic acidosis is common after a single generalized motor seizure and resolves with termination of the seizure. Cerebral metabolic demand increases greatly with GCSE; however, cerebral blood flow and oxygenation are thought to be preserved or even elevated early in the course of GCSE. Research with paralyzed and artificially ventilated animals concluded that neuronal loss after focal or generalized status epilepticus is linked to the abnormal neuronal discharges and not simply to the systemic effects of GCSE. The hippocampus seems especially vulnerable to damage by this mechanism. FrequencyUnited StatesApproximately 50,000-200,000 cases of status epilepticus occur per year (using traditional epidemiologic definitions).2 Mortality/Morbidity
SexMales and females are affected equally. Age
CLINICALHistory
Physical
CausesThe causes of status epilepticus represent an imperfect division into 3 groups.
DIFFERENTIALSDelirium Tremens Delirium, Dementia, and Amnesia Encephalitis Epidural and Subdural Infections Epidural Hematoma Heat Exhaustion and Heatstroke Herpes Simplex Herpes Simplex Encephalitis Hyperosmolar Hyperglycemic Nonketotic Coma Hypertensive Emergencies Hypoglycemia Hyponatremia Hypothyroidism and Myxedema Coma Meningitis Neuroleptic Malignant Syndrome Pediatrics, Febrile Seizures Pediatrics, Meningitis and Encephalitis Pediatrics, Status Epilepticus Stroke, Hemorrhagic Stroke, Ischemic Subarachnoid Hemorrhage Toxicity, Anticholinergic Toxicity, Antidepressant Toxicity, Carbon Monoxide Toxicity, Cocaine Toxicity, Cyanide Toxicity, Cyclic Antidepressants Toxicity, Isoniazid Toxicity, Medication-Induced Dystonic Reactions Withdrawal Syndromes
|
| Drug Name | Lorazepam (Ativan) |
|---|---|
| Description | Sedative hypnotic with short onset of effects and relatively long half-life. By increasing action of GABA, a major inhibitory neurotransmitter in the brain, may depress all levels of CNS, including limbic and reticular formation. Important to monitor patient's BP after administering dose. Adjust as necessary. |
| Adult Dose | 4 mg IV slowly at 2 mg/min; if seizure continues or recurs after 10-15 min, administer an additional 4 mg IV slowly at 2 mg/min |
| Pediatric Dose | Infants and children: 0.1 mg/kg IV slowly over 2-5 min; repeat prn in 10-15 min at 0.05 mg/kg; not to exceed 4 mg/dose Adolescents: 0.07 mg/kg IV slowly over 2-5 min; repeat in 10-15 min prn; not to exceed 4 mg/dose |
| Contraindications | Documented hypersensitivity; preexisting CNS hypotension; depression; narrow-angle glaucoma |
| Interactions | Alcohol, phenothiazines, barbiturates, and MAOIs increase CNS toxicity |
| Pregnancy | D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus |
| Precautions | Caution in renal or hepatic impairment, myasthenia gravis, organic brain syndrome, or Parkinson disease |
| Drug Name | Diazepam (Diastat, Valium) |
|---|---|
| Description | Depresses all levels of CNS (eg, limbic and reticular formation), possibly by increasing activity of GABA. Individualize dosage and increase cautiously to avoid adverse effects. |
| Adult Dose | 5-10 mg IV q10-20min; repeat in 2-4 h prn; not to exceed 30 mg/8 h |
| Pediatric Dose | 0.05-0.3 mg/kg/dose IV over 2-3 min q15-30min; repeat in 2-4 h prn; not to exceed 10 mg |
| Contraindications | Documented hypersensitivity; narrow-angle glaucoma |
| Interactions | Phenothiazines, barbiturates, alcohols, and MAOIs increase toxicity |
| Pregnancy | D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus |
| Precautions | Caution with other CNS depressants, low albumin levels, or hepatic disease (may increase toxicity) |
| Drug Name | Midazolam (Versed) |
|---|---|
| Description | Used as alternative in termination of refractory status epilepticus. Because midazolam is water soluble, takes approximately 3 times longer than diazepam to peak EEG effects. Thus, clinician must wait 2-3 min to fully evaluate sedative effects before initiating procedure or repeating dose. |
| Adult Dose | Loading dose: 0.2 mg/kg IV Continuous infusion: 0.1-0.4 mg/kg/h 10-15 mg IM (when other access impossible) Intubation and pressor support are necessary |
| Pediatric Dose | Loading dose: 0.15 mg/kg IV Maintenance dose: 1 mcg/kg/min; titrate dose upward q5min until clinical seizure activity controlled |
| Contraindications | Documented hypersensitivity; preexisting hypotension; narrow-angle glaucoma; sensitivity to propylene glycol (diluent) |
| Interactions | Theophylline may antagonize sedative effects; narcotics and erythromycin may accentuate sedative effects because of decreased clearance |
| Pregnancy | D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus |
| Precautions | Caution in congestive heart failure, pulmonary disease, renal impairment, and hepatic failure |
These agents are used to terminate clinical and electrical seizure activity as rapidly as possible and to prevent seizure recurrence.
| Drug Name | Phenytoin (Dilantin) |
|---|---|
| Description | May act in motor cortex, where it may inhibit spread of seizure activity. Activity of brainstem centers responsible for tonic phase of grand mal seizures also may be inhibited. Dose should be individualized. Administer larger dose before retiring if dose cannot be divided equally. |
| Adult Dose | Loading dose: 18-20 mg/kg IV; hypotension may necessitate slowing administration rate; rate not to exceed 50 mg/min (hypotension and arrhythmias can otherwise occur); if status epilepticus persists, may increase to total of 30 mg/kg |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity; sinoatrial block; second- and third-degree AV block; sinus bradycardia; Adams-Stokes syndrome |
| Interactions | Amiodarone, benzodiazepines, chloramphenicol, cimetidine, fluconazole, isoniazid, metronidazole, miconazole, phenylbutazone, succinimides, sulfonamides, omeprazole, phenacemide, disulfiram, ethanol (acute ingestion), trimethoprim, and valproic acid may increase toxicity Barbiturates, diazoxide, ethanol (chronic ingestion), rifampin, antacids, charcoal, carbamazepine, theophylline, and sucralfate may decrease effects May decrease effects of acetaminophen, corticosteroids, dicumarol, disopyramide, doxycycline, estrogens, haloperidol, amiodarone, carbamazepine, cardiac glycosides, quinidine, theophylline, methadone, metyrapone, mexiletine, oral contraceptives, and valproic acid |
| Pregnancy | D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus |
| Precautions | Perform blood counts and urinalysis when therapy is begun and at monthly intervals for several months thereafter to monitor for blood dyscrasias; discontinue use if skin rash appears, and do not resume use if rash is exfoliative, bullous or purpuric; rapid IV infusion may result in death from cardiac arrest, marked by QRS widening; caution in acute intermittent porphyria and diabetes (may elevate blood glucose level); discontinue use if hepatic dysfunction occurs |
| Drug Name | Fosphenytoin (Cerebyx) |
|---|---|
| Description | Diphosphate ester salt of phenytoin, which acts as water-soluble prodrug of phenytoin. Following administration, plasma esterases convert fosphenytoin to phosphate, formaldehyde, and phenytoin. Phenytoin, in turn, stabilizes neuronal membranes and decreases seizure activity. To avoid need to perform molecular weight-based adjustments when converting between fosphenytoin and phenytoin sodium doses, dose is expressed as phenytoin sodium equivalents (PE). Although can be administered IV/IM, IV is route of choice and should be used in emergency situations. Since full antiepileptic effect of phenytoin, whether given as fosphenytoin or parenteral phenytoin, is not immediate, coadministration of an IV benzodiazepine usually necessary to control GCSE. IM administration of this medication has been approved. However IV still route of choice for status epilepticus. Cardiac monitoring required when administered IV but not required for IM administration. |
| Adult Dose | 15-20 mg PE/kg IV/IM at rate of 100-150 mg PE/min; if status epilepticus persists, may increase to total of 30 mg/kg |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity; sinoatrial block; second- and third-degree AV block; Adams-Stokes syndrome |
| Interactions | Amiodarone, benzodiazepines, chloramphenicol, cimetidine, disulfiram, ethanol (acute ingestion), omeprazole, phenacemide, phenylbutazone, succinimides, fluconazole, isoniazid, metronidazole, miconazole, sulfonamides, trimethoprim, and valproic acid may increase toxicity Barbiturates, carbamazepine, theophylline, diazoxide, ethanol (chronic ingestion), rifampin, antacids, charcoal, and sucralfate may decrease effects May decrease effects of acetaminophen, corticosteroids, dicumarol, disopyramide, doxycycline, estrogens, haloperidol, amiodarone, carbamazepine, cardiac glycosides, methadone, metyrapone, mexiletine, oral contraceptives, quinidine, theophylline, and valproic acid |
| Pregnancy | D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus |
| Precautions | Blood dyscrasias have occurred—perform blood counts and urinalysis when therapy is begun and at monthly intervals for several months thereafter; discontinue use if skin rash appears; do not resume if rash is exfoliative, bullous, or purpuric; death from cardiac arrest has occurred after too-rapid IV administration, preceded sometimes by marked QRS widening; administer cautiously to patients with acute intermittent porphyria; exercise caution when administering to diabetics (may raise blood glucose levels); discontinue drug if hepatic dysfunction occurs |
These agents stabilize the neuronal membrane so the neuron is less permeable to ions. This prevents the initiation and transmission of nerve impulses, thereby producing the local anesthetic effects. In status epilepticus, lidocaine is indicated during refractory status only and is supported only by anecdotal reports. The consensus seems to be moving toward propofol or midazolam infusions for refractory status epilepticus.
| Drug Name | Propofol (Diprivan) |
|---|---|
| Description | Phenolic compound unrelated to other types of anticonvulsants. Has general anesthetic properties when administered IV. Growing anecdotal reports of use in refractory status epilepticus. Intubation and ventilation required. Hypotension may require treatment. |
| Adult Dose | Loading dose: 2 mg/kg IV Maintenance dose: 0.1-0.2 mg/kg/min (6-12 mg/kg/h) IV |
| Pediatric Dose | Not established Recommended dose: 2-2.8 mg/kg IV |
| Contraindications | Documented hypersensitivity; patients not mechanically ventilated |
| Interactions | Reduce dose when administered concomitantly with benzodiazepines, opiates, phenothiazines, ethanol, or narcotics; may potentiate neuromuscular blockade of vecuronium; theophylline may weaken effects, and dose increase may be needed |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Do not administer with blood or blood products using same IV catheter; patients may develop apnea; may experience decrease in systemic vascular resistance, leading to hypotension |
This class of anticonvulsant may be useful when the condition fails to respond to phenytoin and benzodiazepines. This is the commonly used third-line drug, but midazolam, propofol, and others are increasingly used in preference to phenobarbital, although no rigorous evidence supports the use of one third-line drug over another.
| Drug Name | Phenobarbital (Luminal, Barbita) |
|---|---|
| Description | Exhibits anticonvulsant activity in anesthetic doses. In status epilepticus, important to achieve therapeutic levels as quickly as possible. IV dose may require approximately 15 min to attain peak levels in brain. If IM route chosen, administer into large muscle such as gluteus maximus or vastus lateralis or other areas where risk of encountering nerve trunk or major artery is low. Permanent neurologic deficit may result from injection into or near peripheral nerves. Restrict IV use to conditions in which other routes not possible, either because patient is unconscious or because prompt action required. If used to terminate GCSE, administer up to 15-20 mg/kg. Ventilation and intubation may be necessary. Hypotension may require treatment. A trend is to recommend agents other than phenobarbital (propofol, midazolam, other barbiturates) for refractory status epilepticus. |
| Adult Dose | 15-20 mg/kg IV; maximum infusion rate of 100 mg/min |
| Pediatric Dose | 15-20 mg/kg over 10-15 min IV in single or divided dose Some patients may require 5 mg/kg/dose IV q15-30min until seizure controlled or 40 mg/kg administered |
| Contraindications | Documented hypersensitivity; severe respiratory disease; marked impairment of liver function; nephritis |
| Interactions | May decrease effects of chloramphenicol, digitoxin, corticosteroids, carbamazepine, theophylline, verapamil, metronidazole, and anticoagulants (patients stabilized on anticoagulants may require dosage adjustments if added to or withdrawn from their regimen); alcohol may produce additive CNS effects and death; chloramphenicol, valproic acid, and MAOIs may increase toxicity; rifampin may decrease effects; induction of microsomal enzymes may decrease effects of oral contraceptives in women (must use additional contraceptive methods to prevent unwanted pregnancy; menstrual irregularities may also occur) |
| Pregnancy | D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus |
| Precautions | In prolonged therapy, evaluate hematopoietic, renal, hepatic, and other organ systems; caution in fever, hyperthyroidism, diabetes mellitus, and severe anemia since adverse reactions can occur; caution in myasthenia gravis and myxedema |
| Drug Name | Pentobarbital (Nembutal) |
|---|---|
| Description | Short-acting barbiturate with sedative, hypnotic, and anticonvulsant properties. Can produce mood alteration at all levels of CNS. Use only in refractory status when other agents have failed. Patients need intubation and respiratory support. |
| Adult Dose | Loading dose: 12 mg/kg IV Maintenance dose: 5 mg/kg/h IV infusion; titrate to EEG inactivity |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity; liver failure |
| Interactions | Alcohol may produce additive CNS effects and death; chloramphenicol may inhibit metabolism; may enhance chloramphenicol metabolism; MAOIs may enhance sedative effects; valproic acid appears to decrease metabolism, increasing toxicity; can decrease effects of anticoagulants (patients may require dosage adjustments if barbiturates added to or withdrawn from regimen); decreased contraceptive effect may occur because of induction of microsomal enzymes (alternate form of birth control suggested); may decrease corticosteroid and digitoxin effects through induction of hepatic microsomal enzymes, which increase metabolism; decreases theophylline levels and may decrease effects; may decrease verapamil bioavailability |
| Pregnancy | D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus |
| Precautions | Patient may become tolerant to hypnotic effects; caution in hypovolemic shock, respiratory dysfunction, renal dysfunction, congestive heart failure, previous addiction to sedative hypnotics |
Article Last Updated: Sep 13, 2007